Hall Laurie J Trustee Raises Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Hall Laurie J Trustee increased its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 13.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,742 shares of the company’s stock after purchasing an additional 327 shares during the period. Hall Laurie J Trustee’s holdings in GE HealthCare Technologies were worth $214,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Artemis Investment Management LLP lifted its stake in GE HealthCare Technologies by 15.4% in the fourth quarter. Artemis Investment Management LLP now owns 59,472 shares of the company’s stock valued at $4,650,000 after buying an additional 7,937 shares during the last quarter. Herbst Group LLC increased its holdings in shares of GE HealthCare Technologies by 25.4% in the 4th quarter. Herbst Group LLC now owns 23,190 shares of the company’s stock valued at $1,813,000 after acquiring an additional 4,690 shares during the period. HB Wealth Management LLC raised its position in GE HealthCare Technologies by 24.5% in the 4th quarter. HB Wealth Management LLC now owns 8,366 shares of the company’s stock valued at $654,000 after purchasing an additional 1,645 shares during the last quarter. Trust Co. of Vermont boosted its stake in GE HealthCare Technologies by 10.6% during the 4th quarter. Trust Co. of Vermont now owns 3,696 shares of the company’s stock worth $289,000 after purchasing an additional 354 shares during the period. Finally, Sanibel Captiva Trust Company Inc. grew its position in GE HealthCare Technologies by 139.9% during the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 7,484 shares of the company’s stock worth $585,000 after purchasing an additional 4,364 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Trading Down 0.3 %

Shares of GE HealthCare Technologies stock opened at $84.74 on Monday. The company has a 50-day moving average of $81.98 and a two-hundred day moving average of $84.43. The stock has a market cap of $38.72 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 2.80 and a beta of 1.11. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a 12-month low of $71.31 and a 12-month high of $94.55.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.08. The firm had revenue of $4.86 billion during the quarter, compared to analysts’ expectations of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. GE HealthCare Technologies’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.99 earnings per share. On average, research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be paid a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio is presently 3.85%.

Insider Buying and Selling at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total value of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

GEHC has been the subject of a number of research reports. Wells Fargo & Company upped their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Stifel Nicolaus increased their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Evercore ISI increased their price target on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, UBS Group lowered shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average price target of $96.00.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.